EGFR-TKIs在非小细胞肺癌中的耐药性及耐药后治疗方案的研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (595 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become a first-line inhibitor of epidermal growth factor receptor mutation-positive non-small cell lung cancer. Clinical effective rate can reach 70%, and the overall survival time is two to twenty-four months. It has great advantages over traditional chemotherapy, and the incidence rate of adverse reaction is low. However, the resistance of EGFR-TKIs is almost inevitable, after nine to thirteen months of EGFR-TKIs treatment, drug resistance will appear, and the disease will progress rapidly again. This paper reviews research progress on drug resistance of EGFR-TKIs in non-small cell lung cancer and treatment plan after drug resistance.

Key words： Epidermal growth factor receptor tyrosine kinase inhibitors Non-small cell lung cancer Resistance mechanism Treatment plan after drug resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Mengru CAO Dedong GE Wei

Cite this article:

ZHANG Mengru CAO Dedong GE Wei. Research progress on drug resistance of EGFR-TKIs in non-small cell lung cancer and treatment plan after drug resistance#br#[J]. 中国医药导报, 2021, 18(30): 50-52,59.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I30/50

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] 王克万，杨开军，欧阳辉，等.驱动基因阳性非小细胞肺癌脑转移的个体化综合治疗[J].广东医学，2019，40（1）：41-45.
[3] Shi Y，Au JS，Thongprasert S，et al. A propective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology（PIONEER） [J]. J Thorac Oncol，2014，9（2）：154-162.
[4] 李向莲，唐雪莉，李幼平，等.EGFR-TKI与化疗比较一线治疗晚期非小细胞肺癌有效性和安全性的系统评价[J].中国循证医学杂志，2016，16（2）：191-199.
[5] Gao W，He J，Jin SD，et al. Association of initial epidermal growth factor receptor tyrosine kinase inhibitors treatment and EGFR exon 19 deletion with frequency of the T790M mutation in non-small cell lung cancer patients after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitors [J]. Onco Targets Ther，2019，12：9495-9504.
[6] Nishikawa S，Kimura H，Koba H，et al. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer（NSCLC） who have developed epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI） resistance [J]. J Thorac Dis，2018，10（3）：1431-1439.
[7] Li XF，Shen WZ，Jin X，et al. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations [J]. Sci Rep，2020，10（1）：11236.
[8] Ou SI，Agarwal N，Ali SM. High MET amplification level as a resistance mechanism to osimertinib （AZD9291） in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression [J]. Lung Cancer，2016， 98：59-61.
[9] Le X，Puri S，Negrao MV，et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC [J]. Clin Cancer Res，2018，24（24）：6195-6203.
[10] Wang SE，Narasanna A，Perez-Torres M，et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors [J]. Cancer Cell，2006， 10（1）：25-38.
[11] Robichaux JP，Elamin YY，Vijayan RSK，et al. Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity [J]. Cancer Cell，2019，36（4）：444.e7-457.e7.
[12] 李静，朱冰.PI3K/AKT信号通路与EGFR-TKIs治疗NSCLC耐药的相关性研究进展[J].重庆医学，2018，47（17）：2340-2343.
[13] 王雷，王明吉，黄磊，等.ABCG2在非小细胞肺癌吉非替尼耐药中的作用研究[J].中国当代医药，2019，26（8）：9-13.
[14] Fernandes Neto JM，Nadal E，Bosdriesz E，et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours [J]. Nat Commun，2020，11（1）：3157.
[15] 魏媛，魏莉，马晓平，等.T790M与晚期NSCLC患者EGFR-TKI继发耐药及预后的相关性[J].中华肿瘤防治杂志，2016，23（6）：364-368.
[16] 王磊，李元明，伊斯拉木江·吐尔逊，等.培美曲塞联合吉非替尼治疗获得性EGFR-TKI耐药晚期NSCLC患者的临床疗效观察[J].临床肺科杂志，2017，22（12）：2279-2282.
[17] 张健.培美曲塞治疗EGFR-TKI获得性耐药晚期NSCLC的疗效观察[J].现代肿瘤医学，2018，26（22）：3578-3581.
[18] 马承贤，蔡梦娇，韩苏夏.DNA损伤修复与肿瘤放射敏感性的研究进展[J].西安交通大学学报：医学版，2020， 41（1）：1-6.
[19] Sun J，Liu N，Qu C，et al. Identifying the genetic pattern of conventional fractionated and hypofractionated radio-therapy using whole genome expression microarray in a non-small-cell lung cancer cell line [J]. Chin J Clin Oncol，2013，40（21）：1280-1283．
[20] Liu N，Wang P. Progress in the study of large fractionation radiotherapy sensitivity and PI3K/AKT/mTOR signaling pathway in non-small-cell lung cancer [J]. Chin Cancer Clin，2013，40（19）：1196-1198．
[21] Ferrara R，Imbimbo M，Malouf R，et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer [J]. Cochrane Database Syst Rev，2020，12（12）：CD013257.
[22] Hu Z，Li M，Chen Z，et al. Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 [J]. Transl Lung Cancer Res，2019，8（6）：1091-1106.
[23] Ruiz-Pati?觡o A，Arrieta O，Cardona AF，et al. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer（NSCLC） compared with chemotherapy （Quijote-CLICaP）[J]. Thorac Cancer，2020，11（2）：353-361.
[24] Gainor JF，Shaw AT. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer：a retrospective analysis [J]. Clin Cancer Res，2016，22（18）：4585-4593.
[25] 张智博，李晔，袁方，等.免疫检查点抑制剂治疗EGFR-TKI耐药晚期非小细胞肺癌的疗效及不良反应[J].中国肿瘤临床，2020，47（1）：24-28.
[26] 凌丰宇，李明，陈青娟，等.贝伐珠单抗联合第一代表皮生长因子受体-酪氨酸激酶抑制剂一线治疗EGFR基因突变阳性晚期非小细胞肺癌的Meta分析[J].肿瘤，2020，40（5）：339-347，354.
[27] Kobayashi N，Hashimoto H，Kamimaki C，et al. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance：protocol of an open-label，phase Ⅱ，multicenter，single-arm trial [J]. Thorac Cancer，2020，11（8）：2125-2129.
[28] Ling Zhang，Lei Sun，Xiao-Yan Mu，et al. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer[J] Chin Med Sci J，2019，34（4）：292-296，305.
[29] Ko R，Shukuya T，Imamura CK，et al. Phase Ⅰ study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations [J]. Transl Lung Cancer Res，2021，10（1）：183-192.
[30] Yu Y，Wang Y，Wu L，et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment：a cohort study [J]. Medicine（Baltimore），2021，100（5）：e23712.